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Abstract
Background: Sleeping sickness, or human African trypanosomiasis (HAT), is a protozoan disease that affects rural
communities in sub-Saharan Africa. Determination of the disease stage, essential for correct treatment, represents a key
issue in the management of patients. In the present study we evaluated the potential of CXCL10, CXCL13, ICAM-1, VCAM-1,
MMP-9, B2MG, neopterin and IgM to complement current methods for staging Trypanosoma brucei gambiense patients.
Methods and Findings: Five hundred and twelve T. b. gambiense HAT patients originated from Angola, Chad and the
Democratic Republic of the Congo (D.R.C.). Their classification as stage 2 (S2) was based on the number of white blood cells
(WBC) (.5/mL) or presence of parasites in the cerebrospinal fluid (CSF). The CSF concentration of the eight markers was first
measured on a training cohort encompassing 100 patients (44 S1 and 56 S2). IgM and neopterin were the best in
discriminating between the two stages of disease with 86.4% and 84.1% specificity respectively, at 100% sensitivity. When
a validation cohort (412 patients) was tested, neopterin (14.3 nmol/L) correctly classified 88% of S1 and S2 patients,
confirming its high staging power. On this second cohort, neopterin also predicted both the presence of parasites, and of
neurological signs, with the same ability as IgM and WBC, the current reference for staging.
Conclusions: This study has demonstrated that neopterin is an excellent biomarker for staging T. b. gambiense HAT patients.
A rapid diagnostic test for detecting this metabolite in CSF could help in more accurate stage determination.
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Introduction
Sleeping sickness, or human African trypanosomiasis (HAT), is
a parasitic disease that affects rural communities in sub-Saharan
Africa [1]. More than 90% of HAT cases are caused by
Trypanosoma brucei gambiense, responsible for the chronic form of
the infection in Western and Central Africa [2]. Sleeping sickness
typically progresses from a haemolymphatic first stage (S1) to
a meningo-encephalitic second stage (S2), when parasites cross the
blood-brain barrier (BBB) and enter the central nervous system
(CNS) [3]. As S1 and S2 patients are treated with different drugs,
a correct determination of the stage of disease is crucial. T. b.
gambiense S1 patients are treated with pentamidine, a drug that
cannot be used to treat S2 patients due to its low diffusion into the
CNS [4]. Most S2 patients were until recently treated with
melarsoprol, a toxic arsenic derivate that can cause fatal
encephalopathy and for which increased treatment failure rates
have been observed in different foci endemic for T. b. gambiense
HAT [4,5]. Since 2006 the use of eflornithine has increased and,
with the subsequent introduction of nifurtimox-eflornithine
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combination therapy (NECT), there has been a drastic reduction
of the use of melarsoprol in all countries endemic for T. b. gambiense
HAT [6,7,8,9]. Despite these new advances, difficulties in
administration of eflornithine and NECT and associated high
costs keep stage determination as a central issue in the
management of HAT patients.
Determination of the stage of disease is currently based on
examination of the cerebrospinal fluid (CSF) for presence of
parasites and counting of white blood cells (WBC). Detection of
parasites by microscopy is a specific method and relatively easy to
use in the field [10], but limited in sensitivity. To reduce the
number of false negatives, i.e. stage 2 patients that would be
wrongly treated with ineffective S1 drugs, parasite detection is
complemented with counting of white blood cells in the CSF.
According to WHO guidelines, S1 is defined as #5 WBC/mL and
absence of trypanosomes in CSF, while S2 is defined as.5 WBC/
mL and/or parasites in CSF [11]. Despite WHO recommenda-
tions, a number of countries apply different thresholds to select the
appropriate treatment [12], highlighting the lack of a generally
accepted gold standard for staging [13]. Furthermore, it has been
shown that some patients having between 5 and 20 WBC per
microliter of CSF without detected parasites, or patients having
#5 WBC and presence of parasites (i.e., early-late stage patients)
can be cured with S1 drugs [14,15].
During the last decade, many studies have been conducted to
rationalise stage determination in sleeping sickness. The use of
PCR as surrogate for parasite detection in CSF showed promising
results [16,17], but there is not enough evidence in the literature to
Table 1. Description of the training and the validation cohorts.
Training cohort (n =100) Validation cohort (n =412)
Stage 1 (n =44) Stage 2 (n =56) Stage 1 (n=184) Stage 2 (n=228)
Demography
Female, n * 19 17 102 98
Age (mean [SD]){ 34.4 [613.4] 31.7 [612.2] 32.4 [614.9] 32.8 [612.7]
Geographical origin
Angola, n 8 13 38 68
Chad, n 8 3 17 13
D.R.C., n 28 40 129 147
CSF examinations
Trypanosome positive, n 0 50 0 166{
WBC/mL (median [range]) 2 [1–5] 278.5 [11–1350] 2 [0–5] 161 [1–2000]
Neurological signs
Absent, n 33 3 142 39
Present, n 10 51 36 186
NA, n || 1 2 6 3
*Fisher’s exact test: training cohort, non significant differences; validation cohort, p value = 0.0133.
{Mann-Whitney U test: training and validation cohort, non significant differences.
{Information not available for one patient.
||NA: not available information.
Stage was defined according to WHO guidelines.
doi:10.1371/journal.pone.0040909.t001
Table 2. Results obtained for the eight markers assessed on the training cohort.
Marker [S2]/[S1] AUC% (95%CI) Cut-off (95% CI) SP% (95% CI) * p value{
IgM [mg/mL] 71.9 99.6 (98.9–100) 3.4 (3.3–21) 86.4 (75–95.5) ,0.0001
Neopterin [nmol/L] 17.6 99.6 (99–100) 14.3 (13.4–30.3) 84.1 (72.7–93.2) ,0.0001
MMP-9 [pg/mL] 38.4 99.4 (98.4–100) 141.2 (126.9–1040) 72.7 (59.1–86.4) ,0.0001
VCAM-1 [ng/mL] 3.8 95.5 (91.7–99.4) 15.2 (14.9–21.1) 68.2 (54.6–81.8) ,0.0001
B2MG [ng/mL] 5.1 98.4 (96.7–100) 965 (927.5–1577) 63.6 (50–77.3) ,0.0001
ICAM-1 [ng/mL] 5.4 97.7 (95.3–100) 1.3 (1.2–2.3) 61.4 (47.7–75) ,0.0001
CXCL10 [pg/mL] 32.8 93.3 (88.9–97.8) 757.3 (706.4–1531.7) 43.2 (29.6–59.1) ,0.0001
CXCL13 [pg/mL] 641.4 97.6 (94.9–100) ,8.2 (,8.2–64.6) 0 (0–0) ,0.0001
Training cohort (n = 100): Stage 1 n = 44; Stage 2 n = 56. Early-late stage patients were not included.
*Sensitivity was set to 100%.
{Mann-Whitney U test.
95%CI = 95% confidence interval; SP% = specificity %; SE% = sensitivity %.
The reported cut-off and SP% correspond to 100% SE.
doi:10.1371/journal.pone.0040909.t002
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define the diagnostic accuracy of PCR in terms of sensitivity and
specificity for stage determination [10]. The most promising results
were obtained with the detection of intrathecal IgM as indicator of
CNS involvement in HAT patients [15,18,19]. Detection of IgM
was also translated into a rapid field test, LATEX/IgM [18,20].
Many other studies that investigated alternative staging markers
highlighted a strong correlation between the levels of cytokines,
chemokines and other immune-mediators in CSF, and disease
progression [21]. In the present study, we assess on a multi-centre
cohort the CSF levels of six promising staging markers: B2MG,
CXCL10, CXCL13, ICAM-1, VCAM-1 and MMP-9
[22,23,24,25,26,27] plus neopterin, an indicator of activation of
Th1 immune response [28], already investigated in the staging of
T. b. gambiense (Krishna S., unpublished) and T. b. rhodesiense [29]
HAT. The concentration of total IgM was also measured on the
same samples, as it currently represents the best alternative to
counting WBC. The ability of all these markers to correctly stratify
patients classified according to WHO staging criteria was first
evaluated on a training cohort comprising 100 T. b. gambiense
patients. The staging power of the best performing marker, was
then validated on a larger multi-centre cohort (n = 412) and
compared to IgM and WBC.
Methods
Ethics Statement
The National Ethical Committees of the countries where
samples were collected (Angola, Chad and the Democratic
Republic of the Congo – D.R.C.) approved the studies. HAT
patients gave written informed consent before enrolment. Chil-
dren (,18 years) or patients with altered mental status, a common
condition in late stage HAT, were included only after written
informed consent from a parent or a guardian. All patients had the
option of withdrawing from the studies at any time.
Patients
Cerebrospinal fluid samples of 1028 patients with evidence of
trypanosomes in blood, lymph or CSF were received at the
University of Geneva. The samples originated from patients
identified through active and passive case finding between 2005
and 2009 in Angola, Chad and the Democratic Republic of the
Congo. Sample collection was done in the context of prospective
diagnostic studies (THARSAT [30], NEUROTRYP [22,23] and
FIND/CD19), or was directed by the WHO for a HAT specimen
bank (Table S1 and Figure S1).
Stage determination and treatment were performed in the
designated treatment centres or by medical teams at the site of
active screening, according to the policies of the national sleeping
sickness control programs. The number of WBCs in CSF was
determined by microscopy, and presence of parasites was de-
termined during WBC counting or by using the modified single
centrifugation method [31]. Samples were aliquoted and stored at
280uC or in liquid nitrogen. The levels of biomarkers were
evaluated on the CSF samples between December 2009 and
August 2010.
For the present study, all patients were classified as S1 or S2
according to WHO guidelines, i.e. S1 when #5 WBC/mL and no
parasites in CSF, S2 when .5 WBC/mL and/or trypanosomes in
CSF, regardless of the cut-offs applied at the country level.
Exclusion criteria were: age ,12 years, spontaneous withdrawal
from the study, insufficient volume of CSF, haemorrhagic CSF
(.100 red cells/mL), or missing information to classify patients as
S1 or S2 according to WHO criteria. Information on the
neurological status of patients, including daytime somnolence,
sensory and gait disturbances, presence of primitive reflexes
(palmomental and perioral reflexes), modified tendon reflexes
(exaggeration or abolition), Babinski’s sign, abnormal movements
such as tremors (fine, diffused and generalized), was recorded
when available. Due to the absence of systematic screening for
malaria or HIV co-infections, we considered their prevalence not
different between S1 and S2 patients.
Five hundred and twelve patients were considered eligible for
the present study and were used to create two study cohorts. A first
training cohort of 100 patients was established with 44 S1 and 56
S2 randomly chosen from among all eligible patients. For the
selection of S2 patients, those considered to be early-late stage (i.e.,
Table 3. Results obtained for IgM and neopterin on the validation cohort after application of the cut-off calculated on the training
cohort.
Marker [S2/S1] AUC% (95% CI) Applied cut-off SP% (95% CI) SE% (95% CI) p value *
IgM [mg/mL] 76.5 96.2 (94.4–98.0) 3.4 86.4 (81–91.3) 91.7 (87.7–95.2) ,0.0001
Neopterin [nmol/L] 14.8 95.2 (93.2–97.1) 14.3 87.5 (82.6–91.9) 88.2 (83.8–92.1) ,0.0001
Validation cohort (n = 412): Stage 1 n = 184; Stage 2 n = 228. Early-late stage patients are included in S2 group.
*Mann-Whitney U test.
doi:10.1371/journal.pone.0040909.t003
Table 4. Results obtained for IgM and neopterin on the validation cohort after application of the cut-off calculated on the training
cohort and removal of early-late stage patients (n = 41).
Marker AUC% (95% CI) Applied cut-off SP% (95% CI) SE% (95% CI)
IgM [mg/mL] 99.2 (98.3–100) 3.4 86.4 (81.5–91.3) 98.9 (97.3–100)
Neopterin [nmol/L] 99 (98–100) 14.3 87.5 (82.6–91.9) 97.9 (95.7–99.5)
95%CI = 95% confidence interval; SP% = specificity %; SE% = sensitivity %.
Early-late stage patients (n = 41), i.e. patients having CSF WBC/mL#5 and presence of parasites in CSF (n = 4) or patients having 5,WBC/mL#20 and absence of parasites
in CSF (n = 37), were excluded from the group of S2 patients.
doi:10.1371/journal.pone.0040909.t004
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patients having 5,WBC/mL #20 and absence of parasites, or
patients having #5 WBC/mL and presence of parasites) [14,15]
were not included. The remaining 412 patients were included in
the second cohort (i.e. the validation cohort). Estimating a staging
AUC $90% for each marker based on the results obtained on the
training cohort, the calculated power of the test on the validation
cohort was equal to 1.
Immunoassay Procedures
Commercially available human ELISA kits were used to
determine CSF levels of CXCL13 (R&D Systems, UK), IgM
(ICL, OR, USA), B2MG (Calbiotech, CA, USA) and neopterin
(BRAHMS, Germany). Multiplex bead suspension assays (mBSA)
were used to measure CXCL10 (Bio-Rad, CA, USA), MMP-9,
VCAM-1 and ICAM-1 (R&D Systems). The assays were
performed following manufacturers’ instructions. For each assay
the limit of detection (LOD) was calculated as the mean
concentration of the lowest standard less 2 standard deviations.
To all outliers (#LOD), a value corresponding to the mean of
LODs divided by 2 was assigned. Variability (CV) between assays,
evaluated using internal quality controls, was below 25%.
Statistical Analysis
Data analysis was performed using IBM SPSS Statistics version
20.0.0 (IBM, NY, USA), GraphPad PRISM version 4.03
(GraphPad Software Inc.) and S+ version 8.1 (TIBCO, Software
Inc.). All statistical tests were two-tailed. Differences between two
groups were assessed with the Mann-Whitney U test. For each
biomarker, receiver-operating characteristic (ROC) curves, area
under the curve (AUC), specificity (SP) and sensitivity (SE) were
calculated from the pROC package [32]. To minimize the
number of false negatives, the staging cut-offs on the training
cohort were calculated as the threshold corresponding to 100%
sensitivity.
On the validation cohort, the specificity and sensitivity for
discrimination between early and late stage patients were obtained
by applying the cut-offs calculated on the training cohort. The
same analysis was done on patients classified according to the
absence (T2) or presence (T+) of parasites in the CSF; or
according to the absence (NS2) or presence (NS+) of neurological
signs. Confidence intervals at the 95% level on AUC, sensitivity,
specificity and cut-off were computed with pROC.
This work conforms to the STARD guidelines for reporting of
studies on diagnostic accuracy.
Results
Training Cohort
When assessed on a the training cohort, comprising 44 early
stage and 56 late stage T. b. gambiense patients (Table 1), the seven
markers (CXCL10, CXCL13, neopterin, B2MG, ICAM-1,
VCAM-1 and MMP-9) showed high ability to discriminate
between the two groups of patients (AUC .90% and p value
,0.0001, Mann-Whitney U test) (Table 2). The same results were
obtained with IgM, confirming its value as a staging marker [18].
To reduce the number of false negatives, i.e. S2 patients wrongly
classified as S1, the threshold corresponding to 100% sensitivity
was calculated for each marker. Only IgM and neopterin were
.80% specific at 100% sensitivity. In particular, with a threshold
concentration of 14.3 nmol/L (13.4–30.3 95% CI), neopterin was
84% specific. Similar results were obtained with IgM (86.4%
specificity) at a threshold concentration of 3.4 mg/mL (3.3–21
95% CI) (Table 2).
Validation Cohort
Neopterin and IgM were then measured on a validation cohort
comprising 184 S1 and 228 S2 T. b. gambiense patients (Table 1).
CSF neopterin at a threshold concentration of 14.3 nmol/L
discriminated between early and late stage patients with 87.5%
specificity (82.6–91.9 95% CI) and 88.2% sensitivity (83.8–92.1
95% CI) (Table 3). This means that 23 out of 184 S1 patients were
classified as stage 2 by neopterin (false positives) and 27 out of 228
Table 5. Detailed description of false negative patients obtained according to neopterin and IgM after removal of early–late stage
patients from S2 group.
FN Patient Neopterin,14.3 nmol/L IgM,3.4 mg/mL WBC/mL Parasites Neurological signs
# 1 Yes Yes 25 Absent Absent
# 2 Yes No 32 Absent Absent
# 3 Yes No 261 Present Present
# 4 Yes Yes 282 Present Present
FN: false negatives.
doi:10.1371/journal.pone.0040909.t005
Table 6. Ability of WBC, IgM and neopterin in discriminating between patients without or with parasites in CSF.
T2 vs. T+
Marker AUC% (95% CI) Applied cut-off SP% (95% CI) SE% (95% CI)
WBC (Cells/mL) 95.1 (92.8–97.4) 5.0 68.6 (62.9–74.3) 98.2 (95.8–100)
IgM [mg/mL] 95.2 (93–97.3) 3.4 71.4 (65.7–77.1) 98.2 (95.8–100)
Neopterin [nmol/L] 96.0 (93.9–98.0) 14.3 75.1 (69.8–80.4) 97.6 (95.2–99.4)
T2: patients without evidence of parasite in CSF (n = 245); T+: patients with parasite detected in CSF (n = 166). Missing information for 1 S2 patient.
95%CI = 95% confidence interval; SP% = specificity %; SE% = sensitivity %.
doi:10.1371/journal.pone.0040909.t006
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S2 were classified as S1 (false negatives). Among these 27 false
negatives, twenty three belonged to the early-late stage group, i.e.
patients having between 5 and 20 WBC/mL with no trypanosomes
in CSF or #5 WBC/mL and presence of trypanosomes in CSF.
When all early-late stage patients (n = 41) were excluded from the
S2 group, the number of false negatives was only 4 patients, thus
increasing the sensitivity of neopterin in determining the disease
stage to 97.9% (95.7–99.5 95% CI), (Table 4). Two of these 4
patients had #32 WBC/mL and neither showed evidence of
parasites in CSF nor presence of neurological signs (Table 5).
With a staging cut-off of 3.4 mg/mL, IgM correctly discrimi-
nated S1 and S2 patients, classified according to WHO guidelines,
with 86.4% (81–91.3 95% CI) specificity (25/184 false positives)
and 91.7% (87.7–95.2 95% CI) sensitivity (19/228 false negatives)
(Table 3). When early-late stage patients were excluded, the
number of false negatives decreased to 2 patients thus increasing
the sensitivity of IgM in disease staging to 98.9% (97.3–100
95%CI) (Table 4, Table 5).
To compare neopterin and IgM with WBC, patients were
classified according to absence or presence of trypanosomes in
CSF or according to absence or presence of neurological signs, as
these two conditions can be indicative of an advanced stage of
disease. The ability of the two markers and WBC to discriminate
between the two groups was then assessed through ROC curves.
Neopterin (14.3 nmol/L) was the best discriminator between
patients without parasites in CSF (n= 245) and those with detected
parasites (n = 166), showing higher specificity (75.1%, 69.8–80.4
95% CI) than WBC (68.6%, 62.9–74.3 95% CI) for similar levels
of sensitivity (Table 6).
When patients were grouped based on the absence (n = 181) or
presence (n = 222) of neurological signs, the specificity and
sensitivity of both neopterin and IgM were comparable to WBC
(Table 7).
Finally we assessed how neopterin and IgM classified early-late
stage patients (n = 41), defined as S2 according to WHO
guidelines. Based on the two markers, respectively 23 (56%) and
17 (41%) of these patients were classified as S1 instead of S2. Most
of the early-late stage patients (71%) were classified as stage 1 by
both neopterin and IgM. However, no relationship between the
presence of neurological signs and the levels of the two markers
could be demonstrated in the analyzed patients (Figure 1).
Discussion
The lack of a generally accepted gold standard highlights the
need of new tools that could replace WBC counting and
complement trypanosome detection in the staging of T. b. gambiense
sleeping sickness patients [13,33]. The aim of the present study
was to compare on a large multi-centre cohort of T. b. gambiense
patients the ability of the best staging markers in CSF proposed in
the literature [13,21,33] to discriminate between S1 and S2 HAT
patients. This is the first time that neopterin, IgM, CXCL13,
ICAM-1, VCAM-1, MMP-9, CXCL10 and B2MG have been
assessed on the same training population encompassing 100 T. b.
gambiense HAT patients. This evaluation allowed a better compar-
ison of their individual performances, leading to the selection of
neopterin as a promising new staging marker for T. b. gambiense
sleeping sickness.
Due to the risk of relapses and even death when S2 patients are
misdiagnosed and treated as S1 patients, a highly sensitive marker
is needed in order to reduce the number of false negative patients.
A cut-off corresponding to 100% sensitivity was thus established
on the training cohort, and neopterin emerged as the most
powerful staging marker with specificity close to that of IgM, the
best alternative to WBC proposed so far.
Neopterin and IgM were further tested on a validation cohort
encompassing 412 T. b. gambiense patients and the cut-offs
calculated on the training cohort applied. The results obtained
confirmed previously published data on the high staging power of
IgM, for which a rapid, field applicable agglutination test was
developed [18], as well as preliminary data on the high correlation
between neopterin and WBC counts (S. Krishna, unpublished).
The decreased sensitivity observed on the validation cohort was
due to the presence of early-late stage patients in the S2 group.
These patients are the most critical because in some cases they
have been reported to be cured with pentamidine [14,34]. When
these patients were omitted from the validation cohort, the
sensitivity of neopterin increased to 97.9% meaning that only 4 S2
patients, including 2 with trypanosomes in the CSF, were classified
as false negatives. The value of neopterin as a staging tool was also
supported by the results obtained for IgM, which showed very
similar performance. Furthermore, both IgM and neopterin were
shown to correlate with presence of parasites in CSF and
neurological signs with the same accuracy as WBC count.
A rapid assay for detection of neopterin in CSF might have
potential to replace WBC counting for diagnosis of the meningo-
encephalitic stage of HAT, in combination with parasite detection
in CSF. These important perspectives in the field of staging do not
find application in the diagnosis of the disease, which is based on
detection of parasite-specific antibodies using the CATT test as
a screening tool, followed by parasitological confirmation of
disease. It might also show potential for assessment of cure after
treatment, within a shorter period compared to IgM and WBC
count [30]. Neopterin is a stable catabolic product of guanosine
triphosphate (GTP) that is produced by interferon (IFN)-c
activated macrophages and dendritic cells [35]. It has been
proposed as a marker of disease activity in tuberculosis [36,37] and
of CNS involvement in HIV and T. b. rhodesiense HAT [29]. A
simple dipstick assay for semi-quantitative detection of neopterin
in serum has already been found useful and practicable for other
Table 7. Ability of WBC, IgM and neopterin in discriminating between patients without or with neurological signs.
NS- vs. NS+
Marker AUC% (95% CI) Applied cut-off SP% (95% CI) SE% (95% CI)
WBC (Cells/mL) 86.2 (82.5–90.0) 5.0 72.4 (65.8–79.0) 83.8 (78.8–88.7)
IgM [mg/mL] 84.5 (80.6–88.5) 3.4 71.8 (65.2–78.5) 80.6 (75.2–85.6)
Neopterin [nmol/L] 88.2 (84.9–91.4) 14.3 78.5 (72.4–84) 81.5 (76.6–86.5)
NS2: patients without neurological signs (n = 181); NS+: patients with neurological signs (n = 222). Missing information for 9 patients.
95%CI = 95% confidence interval; SP% = specificity %; SE% = sensitivity %.
doi:10.1371/journal.pone.0040909.t007
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Figure 1. Classification of HAT patients according to WBC and IgM, or according to WBC and neopterin. A) Comparison of the
classification of HAT patients (validation cohort) according to WBC and IgM. The staging cut-off of 5 WBC/mL recommended by WHO is reported on
the graph as well as the staging cut-off of 3.4 mg/mL for IgM calculated on the training cohort. Black dots represent stage 1 patients, white dots
represent early-late stage patients and gray dots represent stage 2 patients. B) Detailed classification of early-late stage patients (n = 41) according to
IgM. Colours indicate the absence (white) or presence of neurological (black) signs. The staging cut-off of 5 WBC/mL recommended by WHO is
reported on the graph as well as the staging cut-off of 3.4 mg/mL for IgM calculated on the training cohort. C) Comparison of the classification of HAT
patients (validation cohort) according to WBC and neopterin. The staging cut-off of 5 WBC/mL recommended by WHO is reported on the graph as
well as the staging cut-off of 14.3 nmol/L for neopterin calculated on the training cohort. Black dots represent stage 1 patients, white dots represent
early-late stage patients and gray dots represent stage 2 patients. D) Detailed classification of early-late stage patients (n = 41) according to neopterin.
Colours indicate the absence (white) or presence (black) of neurological signs. The staging cut-off of 5 WBC/mL recommended by WHO is reported on
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infectious diseases [38], indicating the potential to assess neopterin
in CSF with a rapid diagnostic test.
The present study had a number of limitations that need to be
considered. An important weakness was the absence of highly
detailed and standardised information on patients’ neurological
status or presence of concomitant infections such as HIV and
malaria, which could help in interpretation of data. The markers
reported here for staging are not specific for HAT. Sleeping
sickness patients are exposed to other infections, and neopterin has
already been proposed as marker for other diseases that are
endemic in Africa [36]. Thus, the effect of concomitant diseases on
the levels of the markers should be investigated further.
Another drawback is the absence of a gold standard to which
the performance of neopterin, as well as the other molecules
analysed, could be compared. In an effort to overcome this
deficiency, the staging performance was correlated to the presence
of parasites in CSF, neurological abnormalities and WBC counts,
parameters used for disease staging in practice. Furthermore,
neopterin was also compared to IgM, already validated as a staging
marker [15,18]. However, within the study cohorts, the methods
used for parasite detection, WBC count and assessing neurological
signs were not standardised, thus reducing the accuracy of original
staging. Finally, the utility of the tested marker, including
neopterin, in correct staging of early-late stage patients, i.e.
patients having between 5 and 20 WBC/mL and no parasites in
CSF, or patients having # 5 WBC/mL and trypanosomes in CSF,
cannot be assessed on the current cohort. Some early-late stage
patients have previously been reported to be cured with
pentamidine [34]. In the studied cohort, some of the early-late
stage patients could have benefited from treatment with S1 drugs,
as suggested by levels of neopterin and IgM that were below the
proposed threshold values.
The markers evaluated in the current study still rely on
examination of CSF, which is the basis of actual staging. Ideally,
alternative markers for staging should be detectable in plasma,
thus avoiding lumbar punctures. Unfortunately, none of the
markers investigated here was able to distinguish between S1 and
S2 patients when measured in plasma (data not shown).
In conclusion this study highlights the value of neopterin in CSF
as a marker for the identification the meningo-encephalitic stage of
gambiense HAT. A rapid diagnostic test for detection of this
metabolite in patients’ CSF could become a valuable alternative to
counting of WBC, still to be combined with parasite detection in
CSF. The value of neopterin for follow-up after treatment should
be investigated as well as its ability to stage Trypanosoma brucei
rhodesiense HAT.
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